Literature DB >> 18242472

Symptom-limited exercise during vasodilator stress: best of both worlds?

Kevin A Bybee, Timothy M Bateman.   

Abstract

Mesh:

Substances:

Year:  2008        PMID: 18242472     DOI: 10.1016/j.nuclcard.2007.11.005

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


× No keyword cloud information.
  29 in total

Review 1.  Transient ischemic dilation: a powerful diagnostic and prognostic finding of stress myocardial perfusion imaging.

Authors:  Michael G McLaughlin; Peter G Danias
Journal:  J Nucl Cardiol       Date:  2002 Nov-Dec       Impact factor: 5.952

Review 2.  Prognostic value of gated myocardial perfusion SPECT.

Authors:  Leslee J Shaw; Ami E Iskandrian
Journal:  J Nucl Cardiol       Date:  2004 Mar-Apr       Impact factor: 5.952

3.  Heart rate response during dipyridamole stress as a predictor of mortality in patients with normal myocardial perfusion and normal electrocardiograms.

Authors:  Rohit Bhatheja; Gary S Francis; Claire E Pothier; Michael S Lauer
Journal:  Am J Cardiol       Date:  2005-05-15       Impact factor: 2.778

4.  Prediction of myocardial infarction versus cardiac death by gated myocardial perfusion SPECT: risk stratification by the amount of stress-induced ischemia and the poststress ejection fraction.

Authors:  T Sharir; G Germano; X Kang; H C Lewin; R Miranda; I Cohen; R D Agafitei; J D Friedman; D S Berman
Journal:  J Nucl Med       Date:  2001-06       Impact factor: 10.057

5.  Incremental prognostic value of adenosine stress myocardial perfusion single-photon emission computed tomography and impact on subsequent management in patients with or suspected of having myocardial ischemia.

Authors:  R Hachamovitch; D S Berman; H Kiat; I Cohen; H Lewin; A Amanullah; X Kang; J Friedman; G A Diamond
Journal:  Am J Cardiol       Date:  1997-08-15       Impact factor: 2.778

6.  Quantitative relation between hemodynamic changes during intravenous adenosine infusion and the magnitude of coronary hyperemia: implications for myocardial perfusion imaging.

Authors:  Rakesh K Mishra; Sharmila Dorbala; Giridhar Logsetty; Alita Hassan; Therese Heinonen; Heinrich R Schelbert; Marcelo F Di Carli
Journal:  J Am Coll Cardiol       Date:  2005-02-15       Impact factor: 24.094

7.  Incremental value of prognostic testing in patients with known or suspected ischemic heart disease: a basis for optimal utilization of exercise technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography.

Authors:  D S Berman; R Hachamovitch; H Kiat; I Cohen; J A Cabico; F P Wang; J D Friedman; G Germano; K Van Train; G A Diamond
Journal:  J Am Coll Cardiol       Date:  1995-09       Impact factor: 24.094

8.  Underestimation of extent and severity of coronary artery disease by dipyridamole stress thallium-201 single-photon emission computed tomographic myocardial perfusion imaging in patients taking antianginal drugs.

Authors:  T Sharir; B Rabinowitz; S Livschitz; I Moalem; J Baron; E Kaplinsky; P Chouraqui
Journal:  J Am Coll Cardiol       Date:  1998-06       Impact factor: 24.094

9.  Transluminal, subselective measurement of coronary artery blood flow velocity and vasodilator reserve in man.

Authors:  R F Wilson; D E Laughlin; P H Ackell; W M Chilian; M D Holida; C J Hartley; M L Armstrong; M L Marcus; C W White
Journal:  Circulation       Date:  1985-07       Impact factor: 29.690

10.  Effect of antianginal medication on resting myocardial perfusion and pharmacologically induced hyperemia.

Authors:  Morten Bøttcher; Jens Refsgaard; Mette M Madsen; Flemming Randsbaek; Anne Kaltoft; Hans Erik Bøtker; Torsten Toftegaard Nielsen
Journal:  J Nucl Cardiol       Date:  2003 Jul-Aug       Impact factor: 5.952

View more
  1 in total

1.  New exercise-dipyridamole combined test for nuclear cardiology in insufficient effort: appropriate diagnostic sensitivity keeping exercise prognosis.

Authors:  Inés Vidal; Mario Beretta; Omar Alonso; Fernando Mut
Journal:  Arq Bras Cardiol       Date:  2015-05-29       Impact factor: 2.000

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.